CATX Perspective Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: CATX

Price (delayed)

$3.24

Market cap

$369.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$319.77M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Highlights
CATX's equity has surged by 68% since the previous quarter and by 22% year-on-year
The company's quick ratio has surged by 70% QoQ but it fell by 48% YoY
Perspective Therapeutics's gross profit has plunged by 58% YoY and by 30% from the previous quarter
The revenue has dropped by 58% year-on-year and by 30% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.isoray.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CATX

CATX stock price

How has the Perspective Therapeutics stock price performed over time
Intraday
-8.99%
1 week
-20%
1 month
-18.59%
1 year
3.51%
YTD
17.82%
QTD
-22.3%

Financial performance

How have Perspective Therapeutics's revenue and profit performed over time
Revenue
$618,000
Gross profit
$618,000
Operating income
-$120.01M
Net income
-$111.13M
Gross margin
100%
Net margin
-17,982.7%
CATX's operating margin has dropped by 186% year-on-year and by 51% since the previous quarter
Perspective Therapeutics's gross profit has plunged by 58% YoY and by 30% from the previous quarter
The revenue has dropped by 58% year-on-year and by 30% since the previous quarter
The net margin has dropped by 54% since the previous quarter

Price vs fundamentals

How does CATX's price correlate with its fundamentals

Growth

What is Perspective Therapeutics's growth rate over time

Valuation

What is Perspective Therapeutics stock price valuation
P/E
N/A
P/B
1.06
P/S
543.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
517.43
Perspective Therapeutics's EPS has decreased by 12% YoY
CATX's equity has surged by 68% since the previous quarter and by 22% year-on-year
CATX's P/B is 6% above its last 4 quarters average of 1.1 but 2.5% below its 5-year quarterly average of 1.2
CATX's P/S is 74% above its last 4 quarters average of 343.1
The revenue has dropped by 58% year-on-year and by 30% since the previous quarter

Efficiency

How efficient is Perspective Therapeutics business performance
Perspective Therapeutics's ROS has plunged by 54% from the previous quarter
The ROE has plunged by 53% YoY
The ROA has decreased by 47% YoY
CATX's ROIC is up by 19% YoY

Dividends

What is CATX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CATX.

Financial health

How did Perspective Therapeutics financials performed over time
The company's quick ratio has surged by 70% QoQ but it fell by 48% YoY
The current ratio has surged by 69% since the previous quarter but it has declined by 49% year-on-year
The debt is 99% smaller than the equity
CATX's equity has surged by 68% since the previous quarter and by 22% year-on-year
The debt to equity has shrunk by 50% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.